|
1. Biologie
|
|
|
Why some cancers are 'born to be bad' [BBC News]
|
|
|
|
|
|
The
studies also revealed that the earliest mutations that lead to kidney
cancer were happening up to half a century before the cancer was
detected. Sir Harpal Kumar, the chief executive of Cancer Research UK,
said the study was "groundbreaking".
|
|
|
|
|
|
|
|
3. Prévention
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
Employees Jump at Genetic Testing. Is That a Good Thing? [NY Times]
|
|
|
|
|
|
The
company has reduced genetic testing costs by using robotics and machine
learning and eliminating tasks like in-person prescreening by doctors.
It charges $249 for hereditary risk screening for eight of the most
common cancers and began offering that price while more established
medical diagnostics firms were charging $4,000 for similar tests.
|
|
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.12.7 Immunothérapies - vaccins
|
|
|
|
5.2 Pharma
|
|
|
Hanmi calls time on troubled Tagrisso rival olmutinib [FierceBiotech]
|
|
|
|
|
|
The
South Korean drugmaker took the decision after struggling to recruit
patients into clinical trials and concluding that the third-generation
EGFR inhibitor was too far behind Tagrisso (osimertinib), AstraZeneca’s
fast-growing rival, to make a commercial success of the drug, according
to a Korea Biomedical Review report.
|
|
|
|
|
|
|
5.6.4 ESMO - Poumon
|
|
|
|
|
|
5.9 AACR
|
|
|
|
5.9.1 AACR - sein
|
|
|
|
5.9.11 AACR - SNC
|
|
|
|
5.9.3 AACR - mélanome
|
|
|
|
|
|
5.9.4 AACR - poumon
|
|
|
|
5.9.6 AACR - prostate
|
|
|
|
5.9.7 AACR - divers
|
|
|
|
|
|
|
5.9.8 AACR - Pharma
|
|
|
|
Blueprint Medicines' Cancer Drug Impresses In Early Study [Forbes]
|
|
|
|
|
|
He
praised the medicine's efficacy, but also raised the problems of trying
to get DNA sequencing data on patients – and search for a "molecular
needle in a haystack." This is, in fact, exactly the strategy being
pursued by Blueprint, BLU-667's maker. The company is betting that even
though RET mutations are rare, occurring in most cases of medullary
thyroid cancer but only 1% to 2% of non-small cell lung cancers. It
turns up, even more rarely, in other cancers, too.
|
|
|
|
|
|
|
5.9.9 AACR - immunothérapies
|
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|
|
6.9 Controverses
|
|
|
|